Guardant Health (NASDAQ: GH) — Company Overview, News & Financial Data
Guardant Health develops cancer-focused blood tests and genomic profiling assays, aiming to improve outcomes in precision oncology.
Guardant Health
Guardant Health is a precision oncology company that develops and commercializes blood tests, tissue assays, and bioinformatics tools for cancer care. The company provides liquid biopsy tests to assist oncologists with treatment selection for advanced cancer, early detection of disease recurrence, and population screening. Its diagnostic portfolio includes tests designed to detect circulating tumor DNA and evaluate actionable genomic alterations across various solid tumors. Guardant Health also collaborates with pharmaceutical partners to accelerate drug development, support clinical trial biomarker evaluation, and co-develop companion diagnostics for targeted therapies globally.
Snapshot
Operations
Products and/or services of Guardant Health
- Guardant360 Portfolio: Liquid biopsy blood tests, including Guardant360 CDx, providing comprehensive genomic profiling and companion diagnostic insights to guide precision therapy selection for advanced stage cancer patients across broad clinical settings.
- Shield Screening Test: Blood-based screening test designed for primary colorectal cancer detection in average-risk adults, providing a non-invasive alternative to traditional colonoscopy and stool-based screening modalities in routine healthcare settings.
- Guardant Reveal: Blood-based minimal residual disease test engineered to detect circulating tumor DNA following cancer treatment, enabling early detection of recurrence and monitoring response in patients with early-stage cancers.
- Guardant TissueNext: Tissue-based genomic profiling test designed to complement liquid biopsy assays by analyzing solid tumor tissue samples when actionable biomarker identification requires tissue-specific mutational analysis and comprehensive genomic evaluation.
- Guardant Infinity Platform: Next-generation genomic and epigenomic profiling platform providing biopharma partners with advanced multi-omic liquid biopsy capabilities to accelerate clinical trial biomarker evaluation and therapy development.
- BioPharma Solutions: Comprehensive oncology research services partnering with pharmaceutical companies to accelerate targeted drug development, support novel biomarker discovery, and co-develop companion diagnostics for novel anti-cancer therapies.
Guardant Health executive team
- Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman
- Dr. AmirAli Talasaz Ph.D.Co-CEO & Director
- Mr. Michael BellChief Financial Officer
- Ms. Darya ChudovaChief Technology Officer
- Mr. John G. Saia J.D.Chief Legal Officer & Corporate Secretary
- Ms. Terilyn Juarez MonroeChief People Officer
- Mr. Andy AmentSenior Vice President of Operations
- Mr. Kumud KaliaChief Information Officer
- Zarak KhurshidVice President of Investor Relations
- Ms. Gulshan Shaver J.D.Senior VP of Legal Affairs & Chief Compliance Officer